<DOC>
	<DOCNO>NCT00689156</DOCNO>
	<brief_summary>The Danish Breast Cancer Cooperative Group ( DBCG ) wish clarify recurrence-free overall life expectancy longer docetaxel cyclophosphamide compare epirubicin cyclophosphamide follow docetaxel patient TOP2A normal operable breast cancer .</brief_summary>
	<brief_title>Epirubicin Not Patients With TOP2A ( Topoisomerase ( DNA ) II Alpha ( 170kD ) ) Normal Early Breast Cancer</brief_title>
	<detailed_description>In DBCG trial 89D 1,200 patient show substitution CMF chemotherapy methotrexate epirubicin improve survival patient primary operable breast cancer . In retrospective evaluation also show approximately 20 % patient 89D tumor numerical change TOP2A gene , patient abnormal TOP2A benefit epirubicin . In current trial DBCG wish clarify recurrence-free overall life expectancy longer docetaxel cyclophosphamide compare epirubicin cyclophosphamide follow docetaxel patient TOP2A normal operable breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Trial Population : 1 . Younger 35 , least 18 year age 2 . Hormone receptornegative tumor ( ER PgRnegative ) 35 75 year age . 3 . Hormone receptorpositive tumor , 35 59 year age present least one follow characteristic : spread lymph node , tumor &gt; 2 cm , degree malignancy IIIII HER2positive . 1 . Signed informed consent 2 . Histologically confirm invasive breast carcinoma microradical remove breast preserving surgery mastectomy accord DBCG 's guideline 3 . TOP2A normal tumor ( score 0.8 2.0 ) 1 . Pregnancy breastfeed 2 . Earlier medical cancer treatment , include docetaxel , epirubicin cyclophosphamide . 3 . Distant metastases bilateral breast cancer ( exclude checking mean chest radiography , bilateral mammography normal blood sample minimum ) . 4 . Other active , malign disease late 5 year , except adequately treat cured carcinoma situ cervix uteri nonmelanoma skin cancer . 5 . Comorbidity score &gt; 3 ( patient score 12 start dose level 1 ) . 6 . Treatment nonapproved product test product late 30 day . 7 . Known severe hypersensitivity docetaxel , epirubicin cyclophosphamide auxiliary agent product .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Epirubicin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>DNA Topoisomerases , Type II</keyword>
</DOC>